Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice

被引:150
作者
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
adherence; preexposure prophylaxis; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; SELF-REPORT; RISK; MEN; SEX; PREVENTION; INFECTION; TENOFOVIR; INTERVENTIONS;
D O I
10.1097/COH.0000000000000220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention.Recent findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies.SummaryPrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 66 条
[1]   Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials [J].
Agot, Kawango ;
Taylor, Douglas ;
Corneli, Amy L. ;
Wang, Meng ;
Ambia, Julie ;
Kashuba, Angela D. M. ;
Parker, Caleb ;
Lemons, Ansley ;
Malahleha, Mookho ;
Lombaard, Johan ;
Van Damme, Lut .
AIDS AND BEHAVIOR, 2015, 19 (05) :743-751
[2]   Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment [J].
Amico, K. R. ;
McMahan, Vanessa ;
Goicochea, Pedro ;
Vargas, Lorena ;
Marcus, Julia L. ;
Grant, Robert M. ;
Liu, Albert .
AIDS AND BEHAVIOR, 2012, 16 (05) :1243-1259
[3]   Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection [J].
Amico, K. Rivet ;
Marcus, Julia L. ;
McMahan, Vanessa ;
Liu, Albert ;
Koester, Kimberly A. ;
Goicochea, Pedro ;
Anderson, Peter L. ;
Glidden, David ;
Guanira, Juan ;
Grant, Robert .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (05) :530-537
[4]   Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence [J].
Amico, K. Rivet ;
Stirratt, Michael J. .
CLINICAL INFECTIOUS DISEASES, 2014, 59 :S55-S60
[5]   Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men [J].
Anderson, Peter L. ;
Glidden, David V. ;
Liu, Albert ;
Buchbinder, Susan ;
Lama, Javier R. ;
Vicente Guanira, Juan ;
McMahan, Vanessa ;
Bushman, Lane R. ;
Casapia, Martin ;
Montoya-Herrera, Orlando ;
Veloso, Valdilea G. ;
Mayer, Kenneth H. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Kallas, Esper Georges ;
Grant, Robert M. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (151)
[6]  
[Anonymous], C RETR OPP INF SEATT
[7]  
[Anonymous], C RETR OPP INF SEATT
[8]  
[Anonymous], PREDICTING EFFECTIVE
[9]  
[Anonymous], 2012, Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects
[10]  
Arnica KR, 9 INT C HIV TREATM P